Media enquiries
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.
Do you have
any question?
Saint-Cloud, France – May 19th, 2021 – Ethypharm announces today that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. This agreement confirms Ethypharm’s commitment to patients whose daily life is altered by pain.
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.